Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
1. Daxor received FDA clearance for a new Blood Volume Analysis system. 2. Revenue increased 73% in the first half of 2025 compared to 2024. 3. Market adoption of BVA technology shows strong growth and clinical validation. 4. Daxor showcases innovations at significant industry events to boost awareness. 5. Company emphasizes commitment to improving patient care with BVA technology.